Navigation Links
Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
Date:6/5/2009

SAN DIEGO, June 5, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 8th Annual Needham Life Sciences Conference on June 11, 2009 at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) at the New York Palace Hotel in New York City. Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial Officer, is scheduled to provide an overview of the company, including its clinical development and research programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for weight management. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 Research ... the addition of Jain PharmaBiotech,s new report ... and Companies" to their offering. ... This report deals with therapeutic drug monitoring, ... patient care by monitoring drug levels in ...
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ) has ... "Cell Therapy - Technologies, Markets and Companies" ... describes and evaluates cell therapy technologies and methods, ... role in the practice of medicine. Hematopoietic stem ... marrow transplants. Role of cells in drug discovery ...
(Date:5/28/2015)... 2015 DryLet, LLC a biotechnology ... such as animal waste reduction, bioremediation, wastewater treatment, ... wastewater treatment plants and restaurant kitchen settings, announced ... Expo, June 3-5 in Des Moines, Iowa. , ... Wall Street Journal article because of its industry-leading ...
(Date:5/28/2015)... 28, 2015  GenVec, Inc. (Nasdaq: GNVC ) ... J. Swirsky , will present a company overview at ... EDT on Thursday, June 4, 2015. ... will be available at the following link:  http://wsw.com/webcast/jeff88/gnvc ... website.  To access, visit www.genvec.com , click on ...
Breaking Biology Technology:Global Therapeutic Drug Monitoring Market 2015-2024 2Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2GenVec To Present At The Jefferies Healthcare Conference 2
... sensing by a team of Rensselaer Polytechnic Institute researchers ... agents and illegal drugs from a distance of 20 ... wave technology, has great potential for homeland security and ... packaging materials and can identify immediately the unique THz ...
... pressing concerns of the day, fear of plague probably isn,t ... whose responsibility it is to combat bioterrorism, plague is among ... like medical researcher Steve Smiley, whose lab at the Trudeau ... the public against weaponized forms of plague. The Institute, which ...
... 15 Precision Therapeutics announced today that its ... recognized as CEO of the Year by the ... http://photos.prnewswire.com/prnh/20101015/NE83126 ) (Photo: http://www.newscom.com/cgi-bin/prnh/20101015/NE83126 ... recognizes the accomplishments of 50 of southwestern Pennsylvania,s ...
Cached Biology Technology:A revolutionary breakthrough in terahertz remote sensing 2Plague researchers race to beat bioterrorists 2Plague researchers race to beat bioterrorists 3Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year 2
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
(Date:4/20/2015)... Calif. , April 20, 2015 Huntington ... Gabriel Valley to implant a new miniaturized, wireless monitoring ... System is the first and only FDA-approved heart failure ... hospital admissions when used by physicians to manage heart ... sensor that is implanted in the pulmonary artery (PA) ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... that died 44,000 years ago in Antarctica have provided ... traditional genetic aging measurements, and suggest those approaches have ... 200 to 600 percent. In other words, a ... 100,000 years old may actually be 200,000 to 600,000 ...
... -- Agricultural soils accumulate trace metals, particularly copper ... wastes (sewage biosolids and manures) and fungicides that are ... for tolerable concentrations of these potentially plant-toxic elements in ... effects of the metals are substantially independent and not ...
... and LAS VEGAS, Nov. 9 CBS Vision, the ... Media Group company, today announced a new research partnership that will ... housed in the MGM Grand Hotel in Las Vegas. , ... one of the county,s leading agencies, will be called Communications ...
Cached Biology News:Ancient penguin DNA raises doubts about accuracy of genetic dating techniques 2Additive copper-zinc interaction affects toxic response in soybean 2CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 2CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 3CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 4
WNV Core Antibody...
HSD17B3 Immunogen: HSD17B3 (NP_000188, 29 a.a. ~ 120 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rad51, N-terminal...
Phospho-mu-Opioid Receptor (Ser375) Antibody...
Biology Products: